This book opens up the world on private equity investment in one of the hottest industries – Biotechnology. The book describes how Europe has fallen behind the US due to under-investment and bad management by the VCs who control the companies.  Detailed analysis shows why it is in VCs' interests to damage the very companies they invest in.